Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 9/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7889527 | 0.85 | METAP1 (0.41) | TDP1L3MBTL1KDM1AMETAP1 | |
| SCHEMBL30785 | 0.82 | TDP1 (0.54) | TDP1L3MBTL1BACE1SIGMAR1 | |
| SCHEMBL17355138 | 0.82 | BACE1 (0.37) | L3MBTL1BACE1SIGMAR1KDM1AMETAP1 | |
| SCHEMBL17355127 | 0.82 | TDP1 (0.43) | TDP1L3MBTL1BACE1SLC18A3SIGMAR1 | |
| SCHEMBL1463869 | 0.81 | TDP1 (0.53) | TDP1L3MBTL1BACE1SIGMAR1 | |
| SCHEMBL20467003 | 0.80 | APP (0.38) | TDP1L3MBTL1BACE1KDM1AMETAP1 | |
| SCHEMBL8778992 | 0.80 | TDP1 (0.39) | TDP1L3MBTL1BACE1SLC18A3SIGMAR1 | |
| SCHEMBL17355132 | 0.79 | BACE1 (0.41) | TDP1L3MBTL1BACE1KDM1AMETAP1 | |
| SCHEMBL7890867 | 0.77 | BACE1 (0.45) | BACE1SIGMAR1 | |
| SCHEMBL21654454 | 0.77 | APP (0.41) | METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406240-B1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS INC (US) | 2015-12-23 | — | — | EP | disclosed |